Antithrombotic therapy in atrial fibrillation: A review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) trial

K. Shivkumar; S. M. Jafri; M. Gheorghiade

doi:10.1016/S0033-0620(96)80018-1

Antithrombotic therapy in atrial fibrillation: A review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) trial

K. Shivkumar, S. M. Jafri^*, M. Gheorghiade

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Review article › peer-review

32 Scopus citations

Abstract

Nonvalvular atrial fibrillation is common and is associated with a high risk of systemic embolism. Recently, several large randomized trials have been completed that have established the efficacy of antithrombotic therapy for both primary and secondary prevention of systemic thromboembolism with an acceptable rate of bleeding complications in these patients. This section of clinical trials review summarizes data from all published randomized trials of antithrombotic therapy in atrial fibrillation. The efficacy of aspirin versus warfarin is analyzed. The role of clinical and echocardiographic findings to stratify patients is also highlighted. The Stroke Prevention in Atrial Fibrillation II trial is discussed in detail.

Original language	English (US)
Pages (from-to)	337-342
Number of pages	6
Journal	Progress in Cardiovascular Diseases
Volume	38
Issue number	4
DOIs	https://doi.org/10.1016/S0033-0620(96)80018-1
State	Published - Jan 1 1996

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/S0033-0620(96)80018-1

Cite this

@article{a9bf637cfe7e4d8b963e0756ab81c2bf,

title = "Antithrombotic therapy in atrial fibrillation: A review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) trial",

abstract = "Nonvalvular atrial fibrillation is common and is associated with a high risk of systemic embolism. Recently, several large randomized trials have been completed that have established the efficacy of antithrombotic therapy for both primary and secondary prevention of systemic thromboembolism with an acceptable rate of bleeding complications in these patients. This section of clinical trials review summarizes data from all published randomized trials of antithrombotic therapy in atrial fibrillation. The efficacy of aspirin versus warfarin is analyzed. The role of clinical and echocardiographic findings to stratify patients is also highlighted. The Stroke Prevention in Atrial Fibrillation II trial is discussed in detail.",

author = "K. Shivkumar and Jafri, {S. M.} and M. Gheorghiade",

year = "1996",

month = jan,

day = "1",

doi = "10.1016/S0033-0620(96)80018-1",

language = "English (US)",

volume = "38",

pages = "337--342",

journal = "Progress in Cardiovascular Diseases",

issn = "0033-0620",

publisher = "W.B. Saunders Ltd",

number = "4",

}

Antithrombotic therapy in atrial fibrillation: A review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) trial. / Shivkumar, K.; Jafri, S. M.; Gheorghiade, M.
In: Progress in Cardiovascular Diseases, Vol. 38, No. 4, 01.01.1996, p. 337-342.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Antithrombotic therapy in atrial fibrillation

T2 - A review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) trial

AU - Shivkumar, K.

AU - Jafri, S. M.

AU - Gheorghiade, M.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Nonvalvular atrial fibrillation is common and is associated with a high risk of systemic embolism. Recently, several large randomized trials have been completed that have established the efficacy of antithrombotic therapy for both primary and secondary prevention of systemic thromboembolism with an acceptable rate of bleeding complications in these patients. This section of clinical trials review summarizes data from all published randomized trials of antithrombotic therapy in atrial fibrillation. The efficacy of aspirin versus warfarin is analyzed. The role of clinical and echocardiographic findings to stratify patients is also highlighted. The Stroke Prevention in Atrial Fibrillation II trial is discussed in detail.

AB - Nonvalvular atrial fibrillation is common and is associated with a high risk of systemic embolism. Recently, several large randomized trials have been completed that have established the efficacy of antithrombotic therapy for both primary and secondary prevention of systemic thromboembolism with an acceptable rate of bleeding complications in these patients. This section of clinical trials review summarizes data from all published randomized trials of antithrombotic therapy in atrial fibrillation. The efficacy of aspirin versus warfarin is analyzed. The role of clinical and echocardiographic findings to stratify patients is also highlighted. The Stroke Prevention in Atrial Fibrillation II trial is discussed in detail.

UR - http://www.scopus.com/inward/record.url?scp=0030029557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030029557&partnerID=8YFLogxK

U2 - 10.1016/S0033-0620(96)80018-1

DO - 10.1016/S0033-0620(96)80018-1

M3 - Review article

C2 - 8552791

AN - SCOPUS:0030029557

SN - 0033-0620

VL - 38

SP - 337

EP - 342

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

IS - 4

ER -

Antithrombotic therapy in atrial fibrillation: A review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) trial

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this